#USA #Pittsburgh #Medical Imaging #MolecuLight #Hayfin

MolecuLight Secures $27.5 Million Investment from Hayfin

MolecuLight Inc., a pioneering global medical device company specializing in point-of-care fluorescence imaging, has recently disclosed securing a hefty investment of $27.5 million from Hayfin Capital Management LLP, a leading institutional investor in the healthcare sector. This strategic partnership is anticipated to significantly speed up the commercialization of MolecuLight's innovative technologies across the United States, Canada, and Europe.

The investment is expected to propel the company's presence in a variety of healthcare settings, including outpatient clinics, independent wound care facilities, podiatric practices, mobile care services, and long-term care centers. The focus on such a diverse range of clinical environments underscores MolecuLight's commitment to revolutionizing wound care through advanced imaging techniques.

MolecuLight’s groundbreaking fluorescence imaging devices serve a critical role in the detection and management of infections within wounds. By allowing healthcare providers to visualize harmful bacteria in real-time, these devices equip clinicians with the necessary insights to make informed treatment decisions. This not only enhances patient outcomes but also aids in reducing healthcare costs through shorter healing times and diminished usage of unnecessary antibiotics.

Anil Amlani, CEO of MolecuLight, expressed his enthusiasm about the partnership with Hayfin. He highlighted that the investment will enable the company to expedite its mission of improving wound treatment globally. Additionally, MolecuLight plans to broaden its reach to healthcare professionals and patients while developing further innovative features, such as thermal imaging and 3D wound visualization, which are set to be announced within the next six months.

Andrew Merrill, Managing Director at Hayfin, also commented on the investment, stating that MolecuLight's imaging device is a top-tier product within the market, complemented by a robust development pipeline. The investment not only complements Hayfin's strategy for supporting cutting-edge healthcare innovations but also aims to satisfy a critical need in wound care, thereby delivering massive benefits for patients, providers, and the healthcare system as a whole.

MolecuLight’s technology is recognized for its ability to offer swift, accurate detection of elevated bacterial concentrations in various wounds and injuries. By facilitating early detection, healthcare providers can formulate more targeted treatment plans, ultimately accelerating healing processes and minimizing the risk of complications.

The multimodal device integrates bacteria detection, wound measurement, and imaging functionalities into a single unit. This streamlines workflows while improving documentation accuracy, making it easier for clinicians to meet the highest standard of care without sacrificing operational efficiency.

For seamless operation, MolecuLight’s devices can be easily integrated with electronic health records, allowing healthcare providers to enhance patient care while optimizing their workflows. This positions MolecuLight as a leader in the field of advanced wound management technology.

With this exciting investment from Hayfin, the prospects for MolecuLight seem bright as they continue to innovate and expand, striving to improve wound care systems globally. For additional details about their groundbreaking medical technologies, visit MolecuLight's website.

About MolecuLight

MolecuLight is at the forefront of point-of-care fluorescence imaging, providing the only FDA-approved Class II diagnostic device for detecting bacteria. Their innovative devices allow healthcare providers to quickly and accurately identify bacterial presence in wounds. This real-time visibility enables healthcare professionals to make informed treatment decisions, thus leading to more efficient care delivery.

About Hayfin

Hayfin Capital Management is a premier alternative asset management firm with approximately €32 billion in assets. Focused on achieving attractive risk-adjusted returns, Hayfin invests across private debt, liquid credit, and private equity solutions. The firm boasts a diverse global team of over 200 seasoned professionals headquartered in London with offices in various major cities around the world.